Neurotoxins exhibiting shortened biological activity

Details for Australian Patent Application No. 2010267963 (hide)

Owner MERZ PHARMA GMBH & CO. KGAA

Inventors Hofmann, Fred; Frevert, Jurgen

Agent Callinan

Pub. Number AU-A-2010267963

PCT Pub. Number WO2011/000929

Priority 61/270,198 02.07.09 US; 09164365.0 02.07.09 EP

Filing date 1 July 2010

Wipo publication date 6 January 2011

International Classifications

C12N 9/52 (2006.01) Enzymes, e.g. ligases (6.) - derived from bacteria

A61K 31/713 (2006.01) - Double-stranded nucleic acids or oligonucleotides

A61K 38/48 (2006.01) Medicinal preparations containing peptides

C07K 14/33 (2006.01) Peptides having more than 20 amino acids

C07K 16/12 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - against material from bacteria

C12N 1/21 (2006.01) Micro-organisms, e.g. protozoa - modified by introduction of foreign genetic material

C12N 15/63 (2006.01) Mutation or genetic engineering - Introduction of foreign genetic material using vectors

C12P 21/02 (2006.01) Preparation of peptides or proteins - having a known sequence of two or more amino acids, e.g. glutathione

Event Publications

22 December 2011 PCT application entered the National Phase

  PCT publication WO2011/000929 Priority application(s): WO2011/000929

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010267964-L-serine to be used as a drug for preventing and/or treating an inflammatory response of the skin

2010267955-Method for the replication, amplification or sequencing of a DNA template